BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Sells $342,180.24 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Rating) CFO Brian C. Stephenson sold 24,424 shares of the company’s stock in a transaction that occurred on Wednesday, May 17th. The stock was sold at an average price of $14.01, for a total transaction of $342,180.24. Following the sale, the chief financial officer now directly owns 36,408 shares in the company, valued at approximately $510,076.08. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

BridgeBio Pharma Stock Down 1.9 %

Shares of NASDAQ:BBIO opened at $13.72 on Friday. The company’s fifty day moving average is $14.73 and its 200 day moving average is $11.58. BridgeBio Pharma, Inc. has a 52 week low of $5.74 and a 52 week high of $19.94. The stock has a market cap of $2.20 billion, a PE ratio of -4.83 and a beta of 0.71.

BridgeBio Pharma (NASDAQ:BBIO – Get Rating) last released its quarterly earnings data on Thursday, May 4th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The firm had revenue of $1.83 million during the quarter, compared to analysts’ expectations of $3.23 million. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.35) EPS. Sell-side analysts anticipate that BridgeBio Pharma, Inc. will post -3.34 EPS for the current year.

Analyst Ratings Changes

BBIO has been the subject of a number of recent analyst reports. Raymond James boosted their price target on shares of BridgeBio Pharma from $17.00 to $29.00 and gave the company an “outperform” rating in a research report on Tuesday, March 7th. Cowen initiated coverage on BridgeBio Pharma in a research note on Monday, February 6th. They issued an “outperform” rating on the stock. Cowen initiated coverage on BridgeBio Pharma in a research report on Monday, February 6th. They set an “outperform” rating for the company. Mizuho upped their price objective on shares of BridgeBio Pharma from $23.00 to $29.00 in a research report on Monday, May 8th. Finally, Evercore ISI started coverage on shares of BridgeBio Pharma in a research note on Wednesday, April 19th. They issued an “outperform” rating and a $40.00 target price on the stock. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $26.63.

Institutional Trading of BridgeBio Pharma

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. IFP Advisors Inc purchased a new position in shares of BridgeBio Pharma in the fourth quarter worth $28,000. Clear Street Markets LLC bought a new stake in BridgeBio Pharma in the 1st quarter worth $33,000. Itau Unibanco Holding S.A. purchased a new position in shares of BridgeBio Pharma in the third quarter valued at about $28,000. Quantbot Technologies LP raised its stake in shares of BridgeBio Pharma by 500.0% during the first quarter. Quantbot Technologies LP now owns 4,200 shares of the company’s stock valued at $42,000 after acquiring an additional 3,500 shares during the last quarter. Finally, Sandia Investment Management LP purchased a new stake in shares of BridgeBio Pharma during the first quarter worth about $83,000. Institutional investors own 96.46% of the company’s stock.

About BridgeBio Pharma

(Get Rating)

BridgeBio Pharma, Inc engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.